Immunohistochemistry Thyroid Carcinoma Panel Test

Comprehensive Thyroid Cancer Diagnosis Through Advanced Immunohistochemistry

The Immunohistochemistry Thyroid Carcinoma Panel Test represents a cutting-edge diagnostic approach for accurately identifying and classifying various types of thyroid cancer. This sophisticated panel utilizes immunohistochemistry (IHC) techniques to detect specific protein markers that are characteristic of different thyroid carcinoma subtypes. By providing detailed molecular profiling of thyroid tissue samples, this test enables healthcare providers to make precise diagnoses and develop targeted treatment strategies for patients with thyroid malignancies.

What This Advanced Test Measures and Detects

Our comprehensive Immunohistochemistry Thyroid Carcinoma Panel evaluates seven crucial biomarkers that play essential roles in thyroid cancer diagnosis and classification:

• CK-19 (Cytokeratin 19): A key marker for papillary thyroid carcinoma, helping distinguish it from benign thyroid conditions
• HBME-1 (Hector Battifora Mesothelial Epitope-1): Highly specific for malignant thyroid lesions, particularly papillary and follicular carcinomas
• BRAF V600E Mutation: Identifies the presence of BRAF mutations associated with aggressive papillary thyroid cancer and treatment resistance
• Calcitonin: Essential for diagnosing medullary thyroid carcinoma, a rare but aggressive form of thyroid cancer
• Synaptophysin: Helps identify neuroendocrine differentiation in medullary thyroid carcinomas
• Thyroglobulin: A thyroid-specific protein marker that confirms thyroid tissue origin and aids in cancer classification
• PTF-1 (Pancreatic Transcription Factor 1): Assists in distinguishing thyroid tumors from other malignancies

Who Should Consider This Comprehensive Thyroid Cancer Panel

This advanced diagnostic test is particularly recommended for individuals experiencing the following conditions or clinical scenarios:

• Patients with suspicious thyroid nodules detected during ultrasound or physical examination
• Individuals with fine-needle aspiration biopsy results that are inconclusive or indeterminate
• Patients with confirmed thyroid cancer requiring precise classification for treatment planning
• Individuals with family history of thyroid cancer or multiple endocrine neoplasia syndromes
• Patients presenting with symptoms such as neck swelling, difficulty swallowing, voice changes, or persistent cough
• Those with rapidly growing thyroid nodules or lymph node enlargement in the neck region
• Patients requiring differentiation between benign thyroid conditions and malignant tumors

Significant Benefits of Advanced Thyroid Cancer Testing

Choosing our Immunohistochemistry Thyroid Carcinoma Panel provides numerous advantages for both patients and healthcare providers:

• Precise Cancer Classification: Accurately distinguishes between different thyroid cancer subtypes, enabling targeted treatment approaches
• Improved Diagnostic Accuracy: Reduces diagnostic uncertainty and minimizes the need for repeat biopsies
• Personalized Treatment Planning: Provides molecular information that guides surgical decisions, radiation therapy, and systemic treatments
• Prognostic Information: Certain biomarkers offer insights into disease aggressiveness and potential treatment response
• Comprehensive Evaluation: Multiple biomarker analysis ensures thorough assessment of thyroid tissue characteristics
• Early Detection Capability: Identifies molecular changes that may indicate malignant transformation before obvious morphological changes

Understanding Your Test Results

Interpreting the results of the Immunohistochemistry Thyroid Carcinoma Panel requires specialized medical expertise. Here’s a general guide to understanding what your results might indicate:

• Positive CK-19 and HBME-1: Typically suggests papillary thyroid carcinoma, the most common type of thyroid cancer
• Positive Calcitonin and Synaptophysin: Indicates medullary thyroid carcinoma, which may require different treatment approaches
• BRAF V600E Mutation Positive: Suggests more aggressive papillary thyroid cancer that may benefit from targeted therapies
• Thyroglobulin Expression Patterns: Help distinguish between different thyroid cancer types and confirm thyroid origin
• Combined Marker Profiles: Your healthcare provider will interpret the complete pattern of marker expression to reach a definitive diagnosis

It’s crucial to discuss your specific results with your oncologist or endocrinologist, who will explain the implications for your diagnosis, treatment options, and long-term management plan.

Test Pricing and Availability

Nationwide Accessibility and Convenient Testing

General Genetics Corporation maintains comprehensive testing facilities across the United States, ensuring convenient access to advanced thyroid cancer diagnostics in major metropolitan areas including New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, and San Jose. Our network of certified laboratories follows strict quality control measures and maintains rapid turnaround times to provide timely results for critical medical decisions.

Take Control of Your Thyroid Health Today

Don’t leave your thyroid health to chance. Early and accurate diagnosis is crucial for successful thyroid cancer treatment outcomes. Our Immunohistochemistry Thyroid Carcinoma Panel provides the comprehensive molecular information needed for precise diagnosis and personalized treatment planning.

Schedule your test today by calling our dedicated healthcare line at +1(267) 388-9828 or book your appointment online through our secure patient portal. Our experienced medical team is ready to assist you with convenient testing options and comprehensive support throughout your diagnostic journey.

With competitive pricing at only $132 USD and extensive nationwide coverage, accessing advanced thyroid cancer diagnostics has never been more convenient. Trust General Genetics Corporation for reliable, accurate, and timely immunohistochemistry testing that puts your health first.